BOTHELL, Wash., Oct. 3 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM) today announced that Timothy Falla, Ph. D, Chief
Scientific Officer, will present "Peptide Therapeutics in Wound Management,"
including an overview of the Company's proprietary HB50 and HB107 peptides, at
the Strategic Research Institute's conference titled "Peptides and
Therapeutics Proteins: New Opportunities for Macromolecule Development,
Delivery and Commercialization." The conference will take place on November
17-18, 2005 at the Hilton, Philadelphia City Avenue in Philadelphia, PA and
Dr. Falla will be presenting on the first day of the conference at 3pm.
Helix BioMedix Inc. has a number of preclinical stage peptide therapeutics
that exploit a range of innate immunity functions including antimicrobial,
anti-inflammatory and stimulatory activities. HB50 is a broad spectrum topical
anti-infective that effectively prevents S. aureus wound infection including
infections caused by mupirocin resistant MRSA. Efficacy has also been
demonstrated in this model with a novel lipohexapeptide which has the unusual
feature of maintaining full activity in serum. The modulatory peptide HB107
has demonstrated an ability to accelerate healing in both surgical and burn
wounds including the pig full thickness burn wound model.
The Strategic Research Institute conference will feature presenters from
industry and academic leaders on how proteins and peptides are becoming more
therapeutically viable, as new technologies, delivery systems, and R & D
advances are all converging to make macromolecules more commercially
attractive for the pharmaceutical industry. The conference will feature over
30 speakers from pharma, specialty pharma, and biotech companies. The
conference sections are: 1) Emerging Opportunities in Peptides and
Therapeutics, 2) Advances in Biotherapeutics and 3) New Technologies to
Deliver Peptides, Proteins and Antibodies. Information about the conference
may be obtained from the SRI website at: http://www.srinstitute.com .
About Helix BioMedix
Helix BioMedix, Inc. is an early-stage biotechnology company that has a
portfolio of issued patents that covers six distinct classes of peptides,
covering over 1 million unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Contact:
Helix BioMedix, Inc.
David Kirske,
425-402-8400
dkirske@helixbiomedix.com
Investor Relations:
Cameron Associates
Paul Henning,
212-554-5462
paul@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, or dkirske@helixbiomedix.com; or investors, Paul
Henning of Cameron Associates, +1-212-554-5462, or
paul@cameronassoc.com, for Helix BioMedix, Inc.
|
